CL2021001244A1 - Compuestos antibióticos, métodos de fabricación de los mismos, composiciones farmacéuticas conteniendo los mismos y usos de los mismos - Google Patents
Compuestos antibióticos, métodos de fabricación de los mismos, composiciones farmacéuticas conteniendo los mismos y usos de los mismosInfo
- Publication number
- CL2021001244A1 CL2021001244A1 CL2021001244A CL2021001244A CL2021001244A1 CL 2021001244 A1 CL2021001244 A1 CL 2021001244A1 CL 2021001244 A CL2021001244 A CL 2021001244A CL 2021001244 A CL2021001244 A CL 2021001244A CL 2021001244 A1 CL2021001244 A1 CL 2021001244A1
- Authority
- CL
- Chile
- Prior art keywords
- same
- pharmaceutical compositions
- compositions containing
- manufacturing methods
- antibiotic compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 230000003115 biocidal effect Effects 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/499—Spiro-condensed pyrazines or piperazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención proporciona compuestos de la estructura general (I), que son adecuados como compuestos antibióticos para el tratamiento de infecciones por N. gonorrhoeae e infecciones relacionadas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18205619 | 2018-11-12 | ||
EP18213016 | 2018-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021001244A1 true CL2021001244A1 (es) | 2021-11-19 |
Family
ID=68610175
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021001244A CL2021001244A1 (es) | 2018-11-12 | 2021-05-12 | Compuestos antibióticos, métodos de fabricación de los mismos, composiciones farmacéuticas conteniendo los mismos y usos de los mismos |
CL2022003703A CL2022003703A1 (es) | 2018-11-12 | 2022-12-22 | Compuestos antibióticos, métodos de fabricación de los mismos, composiciones farmacéuticas conteniendo los mismos y usos |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2022003703A CL2022003703A1 (es) | 2018-11-12 | 2022-12-22 | Compuestos antibióticos, métodos de fabricación de los mismos, composiciones farmacéuticas conteniendo los mismos y usos |
Country Status (15)
Country | Link |
---|---|
US (1) | US20230035837A1 (es) |
EP (1) | EP3880675A1 (es) |
JP (1) | JP2022506957A (es) |
KR (1) | KR20210093292A (es) |
CN (1) | CN113272302B (es) |
AU (1) | AU2019380568B2 (es) |
BR (1) | BR112021009106A2 (es) |
CA (1) | CA3119390A1 (es) |
CL (2) | CL2021001244A1 (es) |
IL (2) | IL311894A (es) |
MX (1) | MX2021005535A (es) |
PH (1) | PH12021551058A1 (es) |
SG (1) | SG11202104863RA (es) |
TN (1) | TN2021000092A1 (es) |
WO (1) | WO2020099341A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20240190872A1 (en) * | 2021-03-03 | 2024-06-13 | The Board Of Trustees Of The University Of Illinois | Fabi inhibitors for gram-negative pathogens |
EP4359079A1 (en) | 2021-06-23 | 2024-05-01 | Debiopharm International S.A. | Novel compounds and their use |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
AR025976A1 (es) * | 1999-10-08 | 2002-12-26 | Affinium Pharm Inc | Inhibidores de fab i. |
ES2320984T3 (es) * | 2001-04-06 | 2009-06-01 | Affinium Pharmaceuticals, Inc. | Inhibidores de fab i. |
ATE409485T1 (de) * | 2003-03-17 | 2008-10-15 | Affinium Pharm Inc | Pharmazeutische zusammensetzungen inhibitoren von fab i und weitere antibiotika enthaltend |
KR101299399B1 (ko) * | 2004-06-04 | 2013-08-22 | 아피늄 파마슈티컬스, 인크. | 치료제, 및 그의 제조 및 사용 방법 |
JP2009518399A (ja) * | 2005-12-05 | 2009-05-07 | アフィニウム ファーマシューティカルズ, インク. | Fabi阻害剤および抗菌剤としてのヘテロ環アクリルアミド化合物 |
CN101415701A (zh) * | 2005-12-05 | 2009-04-22 | Affinium医药公司 | 作为fabi抑制剂的杂环丙烯酰胺化合物和抗菌剂 |
US7601716B2 (en) | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
CA2658506C (en) | 2006-07-20 | 2016-01-26 | Affinium Pharmaceuticals, Inc. | Acrylamide derivatives as fab 1 inhibitors |
US8263613B2 (en) | 2007-02-16 | 2012-09-11 | Affinium Pharmaceuticals, Inc. | Salts, prodrugs and polymorphs of fab I inhibitors |
JO3611B1 (ar) | 2011-08-10 | 2020-08-27 | Janssen Sciences Ireland Uc | سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم |
CA2849057C (en) | 2011-09-19 | 2021-05-11 | Vitas Pharma Research Pvt Ltd | Heterocyclic compounds as inhibitors of fatty acid biosynthesis for bacterial infections |
US9062002B2 (en) | 2011-12-02 | 2015-06-23 | Aurigene Discovery Technologies Limited | Substituted pyridine derivatives as FabI inhibitors |
BR122021020778B1 (pt) * | 2012-06-19 | 2022-07-12 | Debiopharm International Sa | Derivados de pró-fármaco de (e)-n-metil-n-((3-metilbenzofuran-2-il) metil)-3-(7-oxo-5,6,7,8-tetraidro- 1, 8- naftirindin-3-il) acrilamida |
CA2879623C (en) * | 2012-08-10 | 2021-11-02 | Janssen Sciences Ireland Uc | Fused bicyclic azole heterocycle as inhibitors of the enzyme fabi |
EP3052476B1 (en) | 2013-09-30 | 2020-07-15 | Guangzhou InnoCare Pharma Tech Co., Ltd. | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease |
-
2019
- 2019-11-11 AU AU2019380568A patent/AU2019380568B2/en active Active
- 2019-11-11 US US17/292,600 patent/US20230035837A1/en active Pending
- 2019-11-11 JP JP2021525117A patent/JP2022506957A/ja active Pending
- 2019-11-11 SG SG11202104863RA patent/SG11202104863RA/en unknown
- 2019-11-11 EP EP19805569.1A patent/EP3880675A1/en active Pending
- 2019-11-11 KR KR1020217018050A patent/KR20210093292A/ko active Search and Examination
- 2019-11-11 CA CA3119390A patent/CA3119390A1/en active Pending
- 2019-11-11 IL IL311894A patent/IL311894A/en unknown
- 2019-11-11 CN CN201980088149.0A patent/CN113272302B/zh active Active
- 2019-11-11 BR BR112021009106-8A patent/BR112021009106A2/pt unknown
- 2019-11-11 WO PCT/EP2019/080903 patent/WO2020099341A1/en active Application Filing
- 2019-11-11 MX MX2021005535A patent/MX2021005535A/es unknown
- 2019-11-11 TN TNP/2021/000092A patent/TN2021000092A1/en unknown
-
2021
- 2021-05-05 IL IL282950A patent/IL282950A/en unknown
- 2021-05-07 PH PH12021551058A patent/PH12021551058A1/en unknown
- 2021-05-12 CL CL2021001244A patent/CL2021001244A1/es unknown
-
2022
- 2022-12-22 CL CL2022003703A patent/CL2022003703A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2019380568B2 (en) | 2024-08-15 |
CN113272302A (zh) | 2021-08-17 |
TN2021000092A1 (en) | 2023-01-05 |
BR112021009106A2 (pt) | 2021-08-10 |
EP3880675A1 (en) | 2021-09-22 |
US20230035837A1 (en) | 2023-02-02 |
SG11202104863RA (en) | 2021-06-29 |
CN113272302B (zh) | 2024-08-13 |
PH12021551058A1 (en) | 2021-11-22 |
KR20210093292A (ko) | 2021-07-27 |
CA3119390A1 (en) | 2020-05-22 |
CL2022003703A1 (es) | 2023-06-09 |
IL311894A (en) | 2024-06-01 |
IL282950A (en) | 2021-06-30 |
MX2021005535A (es) | 2021-09-08 |
WO2020099341A1 (en) | 2020-05-22 |
AU2019380568A1 (en) | 2021-06-17 |
JP2022506957A (ja) | 2022-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP19052302A (es) | Derivados de benzooxazol como inmunomoduladores | |
CO2019000386A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
CO2018007528A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
CO2018005954A2 (es) | Compuestos heteroaromáticos como inhibidores de btk | |
ECSP19057713A (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas para el tratamiento del cáncer | |
ECSP17002135A (es) | Compuestos antiproliferativos y métodos de uso de los mismos | |
CO2019013016A2 (es) | Inhibidores pirazólicos de magl | |
CL2022003703A1 (es) | Compuestos antibióticos, métodos de fabricación de los mismos, composiciones farmacéuticas conteniendo los mismos y usos | |
CL2021001198A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
CO2019013823A2 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
CL2017001539A1 (es) | Compuestos indenil, composiciones farmacéuticas y sus usos médicos de los mismos | |
CO2021002225A2 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
NI201801172A (es) | Nuevos compuestos para el tratamiento de enfermedades parasitarias | |
CL2019002583A1 (es) | Inhibidores duales de magl y faah. | |
DOP2020000100A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 | |
CL2020001062A1 (es) | Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos. | |
CL2018003109A1 (es) | Formas polimorficas de 3-[2-butil-1-(2-dietilamino-etil-1h-benzoimidazol-5-yl]-n-hidroxi-acrilamida y sus usos. | |
CL2021001944A1 (es) | Derivados de aminoácidos para el tratamiento de enfermedades inflamatorias | |
EA202191343A1 (ru) | Антибиотические соединения, способы их получения, фармацевтические композиции, содержащие их, и их применение | |
CR20190028A (es) | Compuestos heterocíclicos como inmunomoduladores | |
CO2019001967A2 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 |